Logo image of ER7.DE

ERAMET (ER7.DE) Stock Fundamental Analysis

FRA:ER7 - Deutsche Boerse Ag - FR0000131757 - Common Stock - Currency: EUR

50.5  -0.85 (-1.66%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ER7. ER7 was compared to 38 industry peers in the Metals & Mining industry. ER7 has a medium profitability rating, but doesn't score so well on its financial health evaluation. ER7 does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year ER7 was profitable.
In the past year ER7 has reported a negative cash flow from operations.
ER7 had positive earnings in 4 of the past 5 years.
ER7 had a positive operating cash flow in 4 of the past 5 years.
ER7.DE Yearly Net Income VS EBIT VS OCF VS FCFER7.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

1.2 Ratios

Looking at the Return On Assets, with a value of 0.22%, ER7 is in line with its industry, outperforming 42.11% of the companies in the same industry.
ER7 has a Return On Equity (0.97%) which is comparable to the rest of the industry.
The Return On Invested Capital of ER7 (1.34%) is worse than 65.79% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ER7 is in line with the industry average of 6.60%.
The 3 year average ROIC (7.29%) for ER7 is well above the current ROIC(1.34%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 0.22%
ROE 0.97%
ROIC 1.34%
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
ER7.DE Yearly ROA, ROE, ROICER7.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60 -80

1.3 Margins

The Profit Margin of ER7 (0.48%) is comparable to the rest of the industry.
ER7's Profit Margin has declined in the last couple of years.
ER7 has a worse Operating Margin (3.27%) than 60.53% of its industry peers.
ER7's Operating Margin has declined in the last couple of years.
ER7's Gross Margin of 66.89% is amongst the best of the industry. ER7 outperforms 89.47% of its industry peers.
In the last couple of years the Gross Margin of ER7 has grown nicely.
Industry RankSector Rank
OM 3.27%
PM (TTM) 0.48%
GM 66.89%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
ER7.DE Yearly Profit, Operating, Gross MarginsER7.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ER7 is destroying value.
ER7 has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ER7 has more shares outstanding
Compared to 1 year ago, ER7 has an improved debt to assets ratio.
ER7.DE Yearly Shares OutstandingER7.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ER7.DE Yearly Total Debt VS Total AssetsER7.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

Based on the Altman-Z score of 1.14, we must say that ER7 is in the distress zone and has some risk of bankruptcy.
ER7 has a Altman-Z score of 1.14. This is in the lower half of the industry: ER7 underperforms 76.32% of its industry peers.
ER7 has a Debt/Equity ratio of 1.35. This is a high value indicating a heavy dependency on external financing.
ER7 has a Debt to Equity ratio of 1.35. This is amonst the worse of the industry: ER7 underperforms 86.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.35
Debt/FCF N/A
Altman-Z 1.14
ROIC/WACC0.15
WACC9.14%
ER7.DE Yearly LT Debt VS Equity VS FCFER7.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

ER7 has a Current Ratio of 1.64. This is a normal value and indicates that ER7 is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.64, ER7 is in line with its industry, outperforming 44.74% of the companies in the same industry.
A Quick Ratio of 1.17 indicates that ER7 should not have too much problems paying its short term obligations.
ER7 has a Quick ratio of 1.17. This is in the better half of the industry: ER7 outperforms 71.05% of its industry peers.
Industry RankSector Rank
Current Ratio 1.64
Quick Ratio 1.17
ER7.DE Yearly Current Assets VS Current LiabilitesER7.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ER7 have decreased strongly by -88.47% in the last year.
The earnings per share for ER7 have been decreasing by -64.00% on average. This is quite bad
The Revenue has decreased by -9.78% in the past year.
ER7 shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.39% yearly.
EPS 1Y (TTM)-88.47%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%406.32%
Revenue 1Y (TTM)-9.78%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-10.08%

3.2 Future

The Earnings Per Share is expected to grow by 31.30% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 5.55% on average over the next years.
EPS Next Y-57.76%
EPS Next 2Y8.24%
EPS Next 3Y31.3%
EPS Next 5YN/A
Revenue Next Year5.37%
Revenue Next 2Y8.73%
Revenue Next 3Y5.55%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ER7.DE Yearly Revenue VS EstimatesER7.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B 4B 5B
ER7.DE Yearly EPS VS EstimatesER7.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 10 20 30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 117.44, ER7 can be considered very expensive at the moment.
Based on the Price/Earnings ratio, ER7 is valued a bit more expensive than 60.53% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.82. ER7 is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 28.49 indicates a quite expensive valuation of ER7.
ER7's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. ER7 is more expensive than 68.42% of the companies in the same industry.
ER7 is valuated rather expensively when we compare the Price/Forward Earnings ratio to 21.76, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 117.44
Fwd PE 28.49
ER7.DE Price Earnings VS Forward Price EarningsER7.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

ER7's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. ER7 is more expensive than 60.53% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.77
ER7.DE Per share dataER7.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60 80 100

4.3 Compensation for Growth

A more expensive valuation may be justified as ER7's earnings are expected to grow with 31.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.24%
EPS Next 3Y31.3%

More info and screens

3

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 3.03%, ER7 has a reasonable but not impressive dividend return.
ER7's Dividend Yield is a higher than the industry average which is at 3.21.
Compared to an average S&P500 Dividend Yield of 2.39, ER7 pays a bit more dividend than the S&P500 average.
Industry RankSector Rank
Dividend Yield 3.03%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
ER7.DE Yearly Dividends per shareER7.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 1 2 3

5.3 Sustainability

307.14% of the earnings are spent on dividend by ER7. This is not a sustainable payout ratio.
DP307.14%
EPS Next 2Y8.24%
EPS Next 3Y31.3%
ER7.DE Yearly Income VS Free CF VS DividendER7.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M
ER7.DE Dividend Payout.ER7.DE Dividend Payout, showing the Payout Ratio.ER7.DE Dividend Payout.PayoutRetained Earnings

More info and screens

ERAMET

FRA:ER7 (5/20/2025, 7:00:00 PM)

50.5

-0.85 (-1.66%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)04-24 2025-04-24
Earnings (Next)07-23 2025-07-23
Inst Owners11.15%
Inst Owner ChangeN/A
Ins Owners0.11%
Ins Owner ChangeN/A
Market Cap1.45B
Analysts76
Price Target64.43 (27.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.03%
Yearly Dividend1.51
Dividend Growth(5Y)N/A
DP307.14%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-24.38%
PT rev (3m)-24.21%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-73.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-2.63%
Revenue NY rev (3m)-5.33%
Valuation
Industry RankSector Rank
PE 117.44
Fwd PE 28.49
P/S 0.5
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB 1.45
EV/EBITDA 9.77
EPS(TTM)0.43
EY0.85%
EPS(NY)1.77
Fwd EY3.51%
FCF(TTM)-28.23
FCFYN/A
OCF(TTM)-4.35
OCFYN/A
SpS101.98
BVpS50.1
TBVpS34.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.22%
ROE 0.97%
ROCE 1.92%
ROIC 1.34%
ROICexc 1.63%
ROICexgc 1.82%
OM 3.27%
PM (TTM) 0.48%
GM 66.89%
FCFM N/A
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
ROICexc(3y)10.98%
ROICexc(5y)11.38%
ROICexgc(3y)12.91%
ROICexgc(5y)13.43%
ROCE(3y)10.76%
ROCE(5y)11.32%
ROICexcg growth 3Y-56.22%
ROICexcg growth 5Y-25.38%
ROICexc growth 3Y-55.33%
ROICexc growth 5Y-24.94%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
F-Score2
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 1.35
Debt/FCF N/A
Debt/EBITDA 7.9
Cap/Depr 454.97%
Cap/Sales 23.42%
Interest Coverage 0.56
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.64
Quick Ratio 1.17
Altman-Z 1.14
F-Score2
WACC9.14%
ROIC/WACC0.15
Cap/Depr(3y)260.42%
Cap/Depr(5y)209.27%
Cap/Sales(3y)18.57%
Cap/Sales(5y)15.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.47%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%406.32%
EPS Next Y-57.76%
EPS Next 2Y8.24%
EPS Next 3Y31.3%
EPS Next 5YN/A
Revenue 1Y (TTM)-9.78%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-10.08%
Revenue Next Year5.37%
Revenue Next 2Y8.73%
Revenue Next 3Y5.55%
Revenue Next 5YN/A
EBIT growth 1Y-23.81%
EBIT growth 3Y-50.34%
EBIT growth 5Y-22.39%
EBIT Next Year127.39%
EBIT Next 3Y42.35%
EBIT Next 5YN/A
FCF growth 1Y-61.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-161.27%
OCF growth 3YN/A
OCF growth 5YN/A